Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Nguyen et al v. NewLink Genetics Corporation et al
Case Number:
1:16-cv-03545
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
February 02, 2021
NewLink Inks $13.5M Deal In Investor Suit Over Cancer Drug
Investors in biopharmaceutical company NewLink Genetics Corp. told a Manhattan federal judge that they'd reached a $13.5 million deal to settle their proposed securities class action accusing the company and its co-founders of misrepresenting details of a pancreatic cancer drug trial.
-
August 01, 2018
NewLink Looks To Nix Investor Suit Over Cancer Drug, Again
Biopharmaceutical company NewLink Genetics Corp. urged a New York federal court Tuesday to dismiss for a second time a proposed investor class action alleging executives' misrepresentations about a pancreatic cancer treatment artificially inflated stock prices, saying the court already determined the statements were "non-actionable opinions."